Impact of MET expression on outcome in BRAFV600E/K advanced melanoma

Histopathology

Volumn 63, Issue 3, 2013, Pages 351-361

  Jubb, Adrian M ^a   Ribas, Antoni ^b   Sosman, Jeffrey A ^c   Mcarthur, Grant A ^d,e   Yan, Yibing ^f   Rost, Sandra ^f   Zhao, Sherry ^a   Koeppen, Hartmut ^f  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Department of Pharmacodynamic Biomarkers Oncology ^*  (United States)

Author keywords

BRAF; HGF; Melanoma; MET; SP44

Indexed keywords

B RAF KINASE; DACARBAZINE; SCATTER FACTOR RECEPTOR; VEMURAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ORYCTOLAGUS CUNICULUS;

BRAF; HGF; MELANOMA; MET; SP44;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTANT PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; RABBITS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84882704157     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12169     Document Type: Article

References (35)

1. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005; 353; 2135-2147.
2. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417; 949-954.
3. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012; 150; 251-263.
4. Krauthammer M, Kong Y, Ha BH et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 2012; 44; 1006-1014.
5. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467; 596-599.
6. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380; 358-365.
7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364; 2507-2516.
8. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012a; 367; 107-114.
9. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012; 366; 707-714.
10. Hoeflich KP, Gray DC, Eby MT et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006; 66; 999-1006.
11. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468; 973-977.
12. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480; 387-390.
13. Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 2012; 3; 724.
14. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468; 968-972.
15. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18; 683-695.
16. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011; 71; 5067-5074.
17. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012b; 367; 1694-1703.
18. Gonzalez R, Ribas A, Daud A et al. Phase IB study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). Ann. Oncol. 2012; 23; ixe1-ixe30.
19. Straussman R, Morikawa T, Shee K et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487; 500-504.
20. Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487; 505-509.
21. Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012; 12; 89-103.
22. Oliner KS, Tang R, Anderson A et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J. Clin. Oncol. 2012; 30; abstract 4005.
23. Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558 g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 2011; 29; abstract 7505.
24. Koeppen H, Januario T, Filvaroff E et al. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Mod. Pathol. 2012; 25; 480A.
25. Dziadziuszko R, Wynes MW, Singh S et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J. Thorac. Oncol. 2012; 7; 340-347.
26. Lee HE, Kim MA, Lee HS et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br. J. Cancer 2012; 107; 325-333.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 2005; 97; 1180-1184.
28. Otsuka T, Takayama H, Sharp R et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998; 58; 5157-5167.
29. Noonan FP, Recio JA, Takayama H et al. Neonatal sunburn and melanoma in mice. Nature 2001; 413; 271-272.
30. Peinado H, Aleckovic M, Lavotshkin S et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012; 18; 883-891.
31. Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 2003; 9; 3362-3368.
32. Ellerhorst JA, Greene VR, Ekmekcioglu S et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 2011; 17; 229-235.
33. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011; 29; 1239-1246.
34. D'Angelo SP, Janjigian YY, Ahye N et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J. Thorac. Oncol. 2012; 7; 1815-1822.
35. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27; 4247-4253.